Drug Combination Details
| General Information of the Combination (ID: C77479) | |||||
|---|---|---|---|---|---|
| Name | Clavulanate NP Info | + | Amoxicillin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Obesity
[ICD-11: 5B81]
|
Phase 2 | [1] | ||
|
Respiratory tract infection
[ICD-11: CA07]
|
Investigative | [2] | |||
|
Staphylococcus infection
[ICD-11: 1C41]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Clinical Trial | |||||
| Experimental
Result(s) |
Amoxicillin/clavulanic acid is a useful therapeutic addition to the existing forms of treatment for amoxicillin-resistant respiratory tract infections. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Experimental
Result(s) |
The production of superoxide radicals by human polymorphonuclear leukocytes was impaired only by the presence of high concentrations (100 mg/l) of both clavulanic acid or the combination amoxycillin/clavulanic acid (4/1). | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Clinical Trial | |||||
| Experimental
Result(s) |
Amoxycillin/clavulanic acid combination was a safe and effective antimicrobial agent for the treatment of respiratory tract infections. | |||||
